Abstract
There have recently been a large number of vaccination studies using mouse models of cutaneous leishmaniasis. These have tended to use either whole attenuated organisms (Howard et al, 1982; Liew et al, 1985) or crude antigen preparations (Liew et al, 1985). Although these vaccine preparations increased resistance if inoculated intravenously (i.v.) or intra-peritoneally (i.p.), they exacerbated infections if administered subcutan-eously (s.c). Intravenous or i.p. vaccination procedures are obviously not acceptable for use with humans. Ideally a vaccine should comprise a purified biochemically defined antigen administered by a cutaneous or intramuscular route without any risk of exacerbating naturally acquired infections. Two antigens have been suggested as potential candidates for successful vaccination, the plasma membrane glycoprotein gp63 and the glycocon-jugate excreted factor (EF). Both antigens are involved in the attachment of the parasite to its host cell, the macrophage (Handman & Goding, 1985; Russell & Wilhelm, 1986), and are found in related forms in all species of Leishmania examined to date (Etges et al, 1985; Colomer-Gould et al, 1985; Handman et al, 1984). We describe here a novel means of presenting these antigens to the immune system and we have successfully vaccinated mice against L.mexicana by the s.c. route.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Chance, M.L., Schnur, L.F., Thomas, S. C. and Peters, W., 1978, The biochemical and serological taxonomy of Leishmania from the Aethiopian zoogeographical region of Africa, Ann.Trop.Med. and Parasitol., 72:533.
Colomer-Gould, V., Quintas, L. G., Keithly, J. and Noguiera, N., 1985, A common major surface antigen on amastigotes and promastigotes of Leishmania species, J.Exp.Med., 162:902.
Etges, R. J., Bouvier, J., Hoffman, R., and Bordier, L., 1985, Evidence that the major surface proteins of three Leishmania species are structurally related, Mol.Biochem.Parasitol., 14:141.
Greenblatt, C. H., 1980, The present and future for cutaneous leishmaniasis, in: “New Developments with Human Vaccines”, A. Mizrahi, M. A. Kling-berg and A. Kohn, eds., Alan R. Liss, New York.
Hamaoka, T., and Fujiwara, H., 1987, Phenotypically and functionally distinct T-cell subsets in anti-tumour responses, Immunol.Today 8:267
Handman, E., and Goding, J. W., 1985, The Leishmania receptor for macrophages is a lipid-containing glycoconjugate, EMBO J., 4:329.
Handman, E., and Mitchell, G. F., 1985, Immunization with Leishmania receptor for macrophages protects mice against cutaneous leishmaniasis, Proc. Natl. Acad. Sci.USA, 82:5910.
Handman, E., Greenblatt, C. H., and Goding, J., 1984, An amphipathic sulphated glycoconjugate of Leishmania characterization with monoclonal antibodies, EMBO J., 3:1206.
Hopp, T. P., 1984, Immunogenicity of a synthetic HBsAg. peptide: enhancement by conjugation to a fatty acid carrier, Mol.Immunol., 21:13.
Howard, J. G., Nicklin, S., Hale, C., and Liew, F.Y., 1982, Prophylactic immunization against experimental leishmaniasis: 1. Protection induced in mice genetically vulnerable to fatal Leishmania tropica infection, J.Immunol., 129:2206.
Kaye, P. M., 1987, Activation of cell-mediated immunity to Leishmania. 1. Primary T-cell activation detected by IL-2 receptor expression, Immunol., 61:345.
Liew, F. Y., and Dhaliwal, J. S., 1987, Distinctive cellular immunity in genetically susceptible BALB/c mice recovered from Leishmania major infection or after subcutaneous immunization with killed parasites, J.Immunol., 138:4450.
Liew, F. Y., Hale, C., and Howard, J. G. 1985, Prophylactic immunization against experimental leishmaniasis. IV. Subcutaneous immunization prevents the induction of protective immunity against fatal Leishmania major infection, J.Immunol., 135:2095.
Manson-Bahr, P. E. C., 1961, Immunity in Kala-azar, Trans.R.Soc.Trop.Med.Hyg. 55:550.
Mayrink, W., Williams, P., DaCosta, C. A., Magalpaes, P. A., Melr, M. N., Dias, M., Oliveira Lima, A., Michaelick, M. S. M., Ferriera Carvahho, E., Barros, G. C., Sessa, P. A., and De Alencar, J. T. A., 1985, An experimental vaccine against American dermal leishmaniasis: experience in the State of Espirito Santo, Brazil, Ann.Trop.Med. Parasitol., 79:259.
Mitchell, G. F. and Handman, E., 1986, The glycoconjugate derived from a Leishmania receptor for macrophages is a suppressogenic, disease promoting antigen in murine cutaneous leishmaniasis, Parasite Immunol. 8:255.
Russell, D. G., and Alexander, J., 1987, Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes, J.Immunol., submitted.
Russell, D. G., and Wilhelm, H., 1986, The involvement of the major surface glycoprotein (gp63) of Leishmania promastigotes in attachment to macrophages, J.Immunol., 136:2613.
Titus, R. G., Ceredig, R., Cerottini, J. C., and Louis, J. A., 1985, Therapeutic effect of anti-L3T4 monoclonal antibody GK 1.5 on cutaneous leishmaniasis in genetically-susceptible BALB/c mice, J.Immunol., 135:2108.
Watari, E., Dietzschold, B., Szohan, G., and Heber-Katy, E., 1987, A synthetic peptide induces long term protection from lethal infection with Herpes simplex virus 2, J.Exp.Med., 165:459.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer Science+Business Media New York
About this chapter
Cite this chapter
Alexander, J., Russell, D.G. (1989). A Novel Method of Vaccination Using Parasite Membrane Antigens. In: Hart, D.T. (eds) Leishmaniasis. NATO ASI Series, vol 171. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1575-9_44
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1575-9_44
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8862-6
Online ISBN: 978-1-4613-1575-9
eBook Packages: Springer Book Archive